PubMed Health⌕ Search

Biomedical subjects

R Clift

Publications and source records attributed to R Clift.

76 records · Page 5Linked to original sources

Thrombopoietin production by human embryonic kidney cells in culture.

Human embryonic kidney cells were maintained in culture in a medium containing lactalbumin hydrolysate for 5 to 6 weeks and the supernatant fluid tested for thrombopoietin content. Thrombopoietin was determined by a bioassay procedure which utilized mice that were in rebound thrombocytosis. The results indicate that the medium from kidney cells in culture contained a factor that stimulates thrombopoiesis in assay mice as measured by per cent 35-S incorporation into platelets. A dose-response relationship was demonstrated between the volume of thrombopoietically active production medium injected and the level of isotope that subsequently appeared in the circulating platelets. Thrombopoietin was not found in control production media. Moreover, thrombopoietin-rich production medium did not contain erythropoietin, erythroginin, or white blood cell-stimulating factors. The results of this study indicate that kidney cells in culture produce a specific thrombopoietic stimulating factor. It seems probable from these in virto data that a site of production of thrombopoietin in vivo is the kidney.

Animals↗

The effects of infection prevention regimens on early infectious complications in marrow transplant patients: a four arm randomized study.

Three hundred and forty-two patients with hematological malignancies underwent allogeneic marrow transplantation from family donors and were allocated to receive 1) no specific infection prophylaxis in a conventional hospital room (control, 100 patients), 2) prophylactic systemic antibiotics (PSA) in a conventional hospital room (PSA group, 101 patients), 3) decontamination and isolation in a laminar air flow (LAF) room (LAF group, 65 patients) and 4) PSA in an LAF room (LAF+PSA group, 76 patients). Patients were studied for bacterial and fungal complications from the day of admission and until engraftment. LAF isolation was discontinued before engraftment in 27% (LAF+PSA group) to 32% (LAF group) of isolated in 26% (LAF+PSA group) to 27% (PSA group) of patients on prophylactic antibiotics. Septicemia occurred in 41%, 22%, 25% and 10% of patients in the control, PSA, LAF and LAF+PSA group, respectively. The incidence of septicemia was significantly less in the LAF+PSA group than in the control and LAF group with the incidence of septicemia significantly higher in the control group than in any of the other three groups. No other risk factors analyzed in proportional hazards regression tests were associated with septicemia acquisition. It is concluded that effective infection prevention modalities significantly reduce infection morbidity in transplant patients. Since most granulocytopenic transplant patients not receiving PSA will receive empiric or therapeutic broad spectrum antibiotics. The use of PSA in or out of LAF isolation is recommended as an effective modality to reduce septicemia acquisition.

Adolescent↗